Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio
- PMID: 26786928
- DOI: 10.1200/JCO.2015.65.0028
Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio
Comment in
-
Reply to A. Indini et al.J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19. J Clin Oncol. 2016. PMID: 26786917 No abstract available.
Comment on
-
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical